Paper27214717
Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A.
Carlsson M and 4 others. Haemophilia, 1997. Cited by 100 papers, by iCite.
Cite this record
ConductScience Library. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Papers, record 27214717. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27214717
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02622646 | Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients | Results |
Source ClinicalTrials.gov
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 100 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42257072 | Impact of Low Dose Prophylaxis (LDP) on spontaneous bleeds in Hemophilia-A: A Bicentre study from Pakistan. | Pak J Med Sci | 2026 | https://conductscience.org/library/papers/42257072 | PubMed |
| 36810557 | Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors. | Hematol Rep | 2023 | https://conductscience.org/library/papers/36810557 | PubMed |
| 35280975 | Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study). | TH Open | 2022 | https://conductscience.org/library/papers/35280975 | PubMed |
| 34531230 | Patient-centered approach to managing factor XIII deficiency. | BMJ Case Rep | 2021 | https://conductscience.org/library/papers/34531230 | PubMed |
| 34407214 | Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. | Cochrane Database Syst Rev | 2021 | https://conductscience.org/library/papers/34407214 | PubMed |
| 34349040 | Clinical Analysis of Hospitalized Patients with Hemophilia A: Single-hemophilia Treatment Center Experience in Korea over 10 years. | Blood Res | 2021 | https://conductscience.org/library/papers/34349040 | PubMed |
| 33733034 | Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. | Res Pract Thromb Haemost | 2021 | https://conductscience.org/library/papers/33733034 | PubMed |
| 33506480 | A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects. | Thromb Haemost | 2021 | https://conductscience.org/library/papers/33506480 | PubMed |
| 32851288 | PK-tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital. | Pediatr Investig | 2019 | https://conductscience.org/library/papers/32851288 | PubMed |
| 32326156 | Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life? | Pharmaceutics | 2020 | https://conductscience.org/library/papers/32326156 | PubMed |
| 30633808 | Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A. | Br J Clin Pharmacol | 2019 | https://conductscience.org/library/papers/30633808 | PubMed |
| 29039750 | Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. | Pharmaceutics | 2017 | https://conductscience.org/library/papers/29039750 | PubMed |
| 28335525 | The History of Clotting Factor Concentrates Pharmacokinetics. | J Clin Med | 2017 | https://conductscience.org/library/papers/28335525 | PubMed |
| 27833753 | Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A. | BMC Hematol | 2016 | https://conductscience.org/library/papers/27833753 | PubMed |
| 27721364 | Pediatric Dosing and Body Size in Biotherapeutics. | Pharmaceutics | 2010 | https://conductscience.org/library/papers/27721364 | PubMed |
| 27390359 | A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. | Haematologica | 2016 | https://conductscience.org/library/papers/27390359 | PubMed |
| 23908669 | Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea. | Korean J Pediatr | 2013 | https://conductscience.org/library/papers/23908669 | PubMed |
| 23620343 | Allometry of factor VIII and informed scaling of next-generation therapeutic proteins. | J Pharm Sci | 2013 | https://conductscience.org/library/papers/23620343 | PubMed |
| 20398185 | Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. | J Thromb Haemost | 2010 | https://conductscience.org/library/papers/20398185 | PubMed |
| 20234780 | Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A. | Vasc Health Risk Manag | 2010 | https://conductscience.org/library/papers/20234780 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/27214717
GET https://conductscience.org/api/papers/v1/27214717/cited_by?page=2